June 20, 2017 / 6:04 AM / a month ago

BRIEF-Galapagos announces successful completion of Phase 1

1 Min Read

June 20 (Reuters) - Galapagos nv

* GALAPAGOS' RESEARCH AND DEVELOPMENT UPDATE 2017: RAPIDLY ADVANCING OUR PRODUCT CANDIDATES

* CYSTIC FIBROSIS: START OF REGULATORY PROCESS NEXT MONTH, PATIENT STUDY WITH FIRST TRIPLE COMBO EXPECTED TO BEGIN IN Q4 '17 IN EUROPE‍​

* ON FILGOTINIB: DARWIN 3: IMPROVED ACTIVITY, CONSISTENT SAFETY PARAMETERS FOR FILGOTINIB; PH2 STUDIES INITIATED IN 6 NEW INDICATIONS

* Topline Data for glpg1690 in Ipf in q3 '17

* OPENING OF US IND AND DOSING OF FIRST OSTEOARTHRITIS PATIENT IN PHASE 1B TRIAL WITH GLPG1972

* CYSTIC FIBROSIS: SUCCESSFUL COMPLETION OF PH1 WITH THREE INDIVIDUAL COMBO COMPONENTS‍​ Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below